Barbara Gayle Duncan is of HALOZYME THERAPEUTICS, INC.. Currently has a direct ownership of 15,754 shares of HALO, which is worth approximately $739,807. The most recent transaction as insider was on Apr 25, 2024, when has been sold 6,501 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 15.8K
0% 3M change
70.26% 12M change
Total Value Held $739,807

Barbara Gayle Duncan Transaction History

Date Transaction Value Shares Traded Shares Held Form
Apr 25 2024
BUY
Grant, award, or other acquisition
-
6,501 Added 29.21%
15,754 Common Stock
May 05 2023
BUY
Grant, award, or other acquisition
-
8,065 Added 46.57%
9,253 Common Stock
Feb 03 2023
BUY
Grant, award, or other acquisition
-
1,188 Added 50.0%
1,188 Common Stock

Also insider at

IMMU
IMMUNOMEDICS INC
AVIR
Atea Pharmaceuticals, Inc. Healthcare
FUSN
Fusion Pharmaceuticals Inc. Healthcare
OVID
Ovid Therapeutics Inc. Healthcare
JNCE
Jounce Therapeutics, Inc. Healthcare
ADAP
Adaptimmune Therapeutics PLC Healthcare
BGD

Barbara Gayle Duncan

Boston, MA

Track Institutional and Insider Activities on HALO

Follow HALOZYME THERAPEUTICS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells HALO shares.

Notify only if

Insider Trading

Get notified when an Halozyme Therapeutics, Inc. insider buys or sells HALO shares.

Notify only if

News

Receive news related to HALOZYME THERAPEUTICS, INC.

Track Activities on HALO